Compare TG Therapeutics Inc (TGTX) vs Trade Desk Inc (TTD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Trade Desk Inc — how do they compare? TG Therapeutics Inc trades at $54.83 (market cap $8.16B), while Trade Desk Inc trades at $12.11 (market cap $5.83B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Trade Desk Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Trade Desk Inc for 72 Days on average.
| TGTX | TTD | |
|---|---|---|
Market Cap | $8.16B | $5.83B |
Volume | 1,735,121 | 15,864,392 |
Sector | Health | Media |
52-Week High | $59.06 | $54.13 |
52-Week Low | $26.94 | $11.92 |
Typical Hold Time | 16 Days | 72 Days |
Enterprise Value | $8.37B | $4.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
The Trade Desk (TTD) trades at $12.08, down 0.12% on the day and showing bearish technical signals with mixed earnings performance. The company maintains strong profitability with 76.9% gross margins and 15.4% ROE, though revenue growth has slowed to 3% in 2026 projections. Recent news highlights competitive pressures from Amazon and Alphabet, with the stock down significantly from its 2024 peak.
While TTD's valuation appears attractive with low P/E and P/S ratios, investors face headwinds from slowing growth and intense competition. The consensus price target of $14.72 suggests moderate upside potential, but near-term catalysts appear limited as the company navigates market share challenges and workforce reductions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Trade Desk Inc
The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →
